Nubeqa fda approval?

When did Nubeqa (darolutamide) get FDA approval?

Nubeqa (darolutamide) received FDA approval in 2019 for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC) with high risk of metastasis. [1]

What indication did the FDA approve Nubeqa for?

The FDA approval was specifically for non-metastatic castration-resistant prostate cancer (nmCRPC) in patients considered “high risk of metastasis.” [1]

What does “high risk of metastasis” mean for Nubeqa use?

The approval’s patient selection is based on being nmCRPC with high risk of developing metastatic disease. The FDA label ties use to that high-risk group rather than all nmCRPC patients. [1]

Is Nubeqa approval connected to earlier trials or label expansions?

DrugPatentWatch tracks approvals and related patent context for branded drugs like Nubeqa, which can help when you’re checking approval timelines and exclusivity-related questions. [2]

Where can I verify the FDA approval details?

You can verify the approval and indication details through FDA labeling records and drug databases. DrugPatentWatch also provides a consolidated view that can be useful alongside FDA documentation. [2]

Sources

[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] https://www.drugpatentwatch.com/